Q3 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vanda Pharmaceuticals Inc (VNDA) reported a strong commercial execution with total net product sales reaching $56.3 million in Q3 2025, up 18% year-over-year.
- Fanapt sales increased by 31% year-over-year, driven by the launch of the bipolar I indication, with prescriptions growing by 35%.
- The company is advancing its pipeline with multiple near-term regulatory milestones, including the Tradipitant NDA for motion sickness and the Bysanti NDA for bipolar I disorder and schizophrenia under FDA review.
- Vanda Pharmaceuticals Inc (VNDA) is strategically investing in its commercial infrastructure, including increased brand visibility through targeted sponsorships.
- HETLIOZ continues to be the market share leader despite the availability of three generic products, demonstrating strong brand loyalty.
- Vanda Pharmaceuticals Inc (VNDA) recorded a net loss of $79.3 million for the first nine months of 2025, compared to a net loss of $14 million for the same period in 2024.
- Operating expenses increased significantly to $269.7 million for the first nine months of 2025, driven by higher SG&A and R&D expenses.
- HETLIOZ net product sales decreased by 3% for the first nine months of 2025 compared to the same period in 2024, due to a decrease in volume.
- PONVORY net product sales decreased by 7% for the first nine months of 2025 compared to the same period in 2024, attributed to a decrease in price net of deductions.
- The company's cash, cash equivalents, and marketable securities decreased by $80.9 million as of September 30, 2025, compared to December 31, 2024.
Hello, and thank you for standing by. My name is Mark and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Vanda Pharmaceuticals Inc earnings conference call. (Operator Instructions)
Now, I would like to turn the call over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead.
Thank you, Mark. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals third quarter 2025 performance. Our third quarter 2025 results were released this afternoon and are available on the SEC's EDGAR system and on our website www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.
Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board; and Tim Williams, our General Counsel. Following my
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
